Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Mirum Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00007020CT.gov Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cholestasis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholalic Acid (this asset) | Mirum Pharmaceuticals, Inc. | P3 | B · 56 |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Linerixibat | GlaxoSmithKline | P3 | BB |
| Maralixibat | Mirum Pharmaceuticals, Inc. | P3 | BB |
| Gabapentin | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | P3 | B |
| Tauroursodeoxycholic | Beijing Trendful Kangjian Medical Information Consulting Limited Company | P3 | B |
| 2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID | Assistance Publique - Hôpitaux de Paris | P3 | B |
| Viosterol | Chulalongkorn University | P4 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
+16 more in the Cholestasis cohort
Other indications for Cholalic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Zellweger Spectrum Disorders | — | P3 | B · 56 |
| Adrenoleukodystrophy | — | P3 | B · 56 |
| Peroxisome Biogenesis Disorder | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Ursodeoxycholic AcidAssistance Publique - Hôpitaux de ParisBB
- LinerixibatGlaxoSmithKlineBB
- MaralixibatMirum Pharmaceuticals, Inc.BB
- GabapentinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)B
- TauroursodeoxycholicBeijing Trendful Kangjian Medical Information Consulting Limited CompanyB
Citation
Floatz Terminal. Cholalic Acid in Cholestasis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cholalic-acid-cholestasis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →